Gemcitabine/anthracycline combinations in metastatic breast cancer

Clinical Breast Cancer

Volumn 3, Issue SUPPL. 1, 2002, Pages

  Zielinski, Christoph C ^a  

^a UNIVERSITY OF VIENNA   (Austria)

Author keywords

Anthracyclines; Combination therapy; Doxorubicin; Epirubicin; Escalating doses; Gemcitabine

Indexed keywords

ANTHRACYCLINE DERIVATIVE; CYCLOPHOSPHAMIDE; DOXORUBICIN; EPIRUBICIN; FLUOROURACIL; GEMCITABINE; NAVELBINE; PACLITAXEL; TAXANE DERIVATIVE;

ADVANCED CANCER; ANAPHYLAXIS; ANEMIA; ARTICLE; BREAST CANCER; BREAST METASTASIS; CANCER COMBINATION CHEMOTHERAPY; CANCER STAGING; CARDIOTOXICITY; CONTROLLED STUDY; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG TOLERABILITY; FEMALE; HUMAN; LEUKOPENIA; MAJOR CLINICAL STUDY; NAUSEA AND VOMITING; NEUTROPENIA; PERIPHERAL NEUROPATHY; REVIEW; THROMBOCYTOPENIA;

EID: 0036077590     PISSN: 15268209     EISSN: None     Source Type: Journal    
DOI: 10.3816/CBC.2002.s.007     Document Type: Article

References (20)

1. Advanced breast cancer: A phase II trial with gemcitabine
2. Phase II study of gemcitabine in patients with metastatic breast cancer
3. Single-agent gemcitabine or docetaxel as second- and third-line treatment of metastatic breast cancer
4. Cytotoxic and hormonal treatment for metastatic breast cancer: A systematic review of published randomized trials involving 31,510 women
5. Preoperative (neoadjuvant) chemotherapy in patients with breast cancer
6. A mathematic model for relating the drug sensitivity of tumors to their spontaneous mutation rate
7. A phase II study of neoadjuvant gemcitabine plus doxorubicin in stage IIIB breast cancer: A preliminary report
8. Phase II studies of neoadjuvant gemcitabine plus anthracyclines in locally advanced breast cancer: A preliminary report
9. 2) in the FEC regimen significantly increases response rates. An international randomised phase III study in metastatic breast cancer
10. Paclitaxel by 3-hour infusion in combination with bolus doxorubicin in women with untreated metastatic breast cancer: High antitumor efficacy and cardiac effects in a dose-finding and sequence-finding study
11. Phase II study of docetaxel, doxorubicin, and cyclophosphamide as first-line chemotherapy for metastatic breast cancer
12. Doxorubicin and paclitaxel versus fluorouracil, doxorubicin, and cyclophosphamide as first-line therapy for women with metastatic breast cancer: Final results of a randomized phase III multicenter trial
13. Preliminary results from an early phase II study of gemcitabine in combination with doxorubicin in advanced breast cancer
14. Gemzar (G) and epirubicin (E) in patients (pts) with metastatic breast cancer (MBC): Final results of a phase I dose-finding study
15. Gemcitabine and epirubicin in first line metastatic breast cancer
16. Gemzar (G) and epirubicin (E) in patients (pts) with metastatic breast cancer (MBC): Results of a phase II trial
17. Biweekly gemcitabine, doxorubicin, and paclitaxel as first-line treatment in metastatic breast cancer. Final results from a phase II trial
18. Gemcitabine, epirubicin and paclitaxel (GET) in metastatic breast cancer (MBC): Preliminary report of a phase I/II study with pharmacokinetic and peripheral blood progenitor cell (PBPC) mobilization assessment
19. The gemcitabine/epirubicin/paclitaxel trials in advanced breast cancer
20. Gemcitabine/epirubicin/paclitaxel (GET) vs 5-fluorouracil/epirubicin/cyclophosphamide (FEC) as first-line treatment in metastatic breast cancer: Interim toxicity analysis of a randomised, European Cooperative Oncology Group (CECOG)